Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer

被引：26

作者：

Baselga, Jose ^{[1
]}

Mendelsohn, John ^{[2
]}

机构：

[1] Hosp Gen Univ Vall DHebron, Barcelona 08035, Spain

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 1997年 / 2卷 / 02期

基金：

美国国家卫生研究院;

关键词：

Tyrosine kinase receptors; monoclonal antibodies; breast cancer; tyrosine kinase inhibitors; epidermal growth factor receptor; HER2/neu; erbB2;

D O I：

10.1023/A:1026355831693

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast carcinomas express high levels of type I tyrosine kinase receptors and their ligands. For these reason therapies directed at these receptors have the potential to be useful anti-cancer agents. A series of monoclonal antibodies (MAbs)(3) directed against the EGF receptor and the closely related erbB2/HER2/neu receptor are currently under evaluation. These MAbs have shown promising preclinical activity and "chimeric" and "humanized" MAbs have been produced in order to obviate the problem of host immune reactions. These antibodies are currently being tested in clinical trials either alone or in combination with chemotherapeutic agents. Clinical activity with anti-HER2/neu MAbs has been documented in patients with advanced breast cancer. In addition, compounds that inhibit receptor tyrosine kinases have shown significant preclinical activity and are potential candidates for clinical testing.

引用

收藏

页码：165 / 174

页数：10

相关论文

共 50 条

[21] Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer [J].

Na, Il-Kang ;

le Coutre, Philipp .

BIOMARKER INSIGHTS, 2015, 10 :29-31

[22] The EGF receptor family as targets for breast cancer therapy [J].

J Baselga .

Breast Cancer Research, 2 (Suppl 1)

[23] Kinases as targets of molecular cancer therapy [J].

Michel, C. ;

Neubauer, A. ;

Burchert, A. .

ONKOLOGE, 2016, 22 (01) :40-48

[24] Exploring receptor tyrosine kinases-inhibitors in Cancer treatments [J].

Metibemu, D. Samuel ;

Akinloye, O. Adeboye ;

Akamo, A. Jamiu ;

Ojo, D. Ajiboye ;

Okeowo, O. Tolulope ;

Omotuyi, I. Olaposi .

EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2019, 20 (01)

[25] Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors [J].

Wagner Ricardo Montor ;

Andrei Ronaldo Oliveira Silva Escartin Salas ;

Fabiana Henriques Machado de Melo .

Molecular Cancer, 17

[26] Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors [J].

Montor, Wagner Ricardo ;

Silva Escartin Salas, Andrei Ronaldo Oliveira ;

Machado de Melo, Fabiana Henriques .

MOLECULAR CANCER, 2018, 17

[27] Targeting receptor tyrosine kinases in gastric cancer [J].

Asahiro Morishita ;

Jian Gong ;

Tsutomu Masaki .

World Journal of Gastroenterology, 2014, (16) :4536-4545

[28] Targeting receptor tyrosine kinases in gastric cancer [J].

Morishita, Asahiro ;

Gong, Jian ;

Masaki, Tsutomu .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (16) :4536-4545

[29] The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer [J].

Hsu, Jennifer L. ;

Hung, Mien-Chie .

CANCER AND METASTASIS REVIEWS, 2016, 35 (04) :575-588

[30] Receptor tyrosine kinases and steroid hormone receptors in breast cancer: Review of recent evidences [J].

Teklemariam, Awgichew Behaile ;

Muche, Zelalem Tilahun ;

Agidew, Melaku Mekonnen ;

Mulu, Anemut Tilahun ;

Zewde, Edgeit Abebe ;

Baye, Nega Dagnew ;

Adugna, Dagnew Getnet ;

Maru, Lemlemu ;

Ayele, Teklie Mengie .

METABOLISM OPEN, 2024, 24

← 1 2 3 4 5 →